Posters

Search Title by author or title

Tecnis Eyhance intraocular lens: our experience!

Poster Details

First Author: A.Marta PORTUGAL

Co Author(s):    A. Abreu   S. Monteiro   M. Pinto   P. Menéres           

Abstract Details

Purpose:

To report the first results with the Tecnis Eyhance intraocular lens (IOL) implanted to patients submitted to cataract surgery.

Setting:

This retrospective study was conducted at the ophthalmology department of a tertiary referral centre in Oporto, Portugal - Centro Hospitalar Universitário do Porto.

Methods:

A retrospective study including patients submitted to Tecnis Eyhance IOL implantation was performed. Best corrected distant visual acuity (BCDVA), uncorrected distant visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA) at 66 cm and uncorrected near visual acuity (UNVA), best corrected near visual acuity (BCNVA), contrast sensitivity (CS) (by Metrovision-MonPack3®) in mesopic (MC) and photopic conditions (PC) and analysis of light scattering in the retina (HD Analyzer®) were evaluated three months after surgery.

Results:

This study included 8 eyes of 4 patients. Before surgery, mean BCDVA was 0.28±0.06logMAR. After surgery, mean BCDVA was 0.00±0.00logMAR, mean UDVA was 0.03±0.03logMAR and mean UIVA was 0.22±0.09logMAR. All patients achieved UNVA J4 or better and BCNVA J1. Objective scatter index (OSI) was significantly lower after surgery (p=0,028). All cases had normal CS results in PC and 50% of cases had abnormal CS results in MC. However, no patient had symptoms of glare or dysphotopsias. In MC, cases with abnormal CS results after surgery had higher OSI values before surgery than cases with normal results (p=0.043).

Conclusions:

Patients who underwent cataract surgery with implantation of Tecnis Eyhance IOL had excellent uncorrected visual acuity at far and very good intermediate vision. CS results were normal in all cases in photopic conditions and abnormal in half of cases in mesopic conditions, but patients denied glare and dysphotopic complaints.

Financial Disclosure:

None

Back to Poster listing